Articles tagged with 'sarah-kremen-2832507' | Cedars-Sinai Medical Center

The Associated Press (AP) recently interviewed neurologist Sarah Kremen, MD, who leads the Alzheimer’s Disease Clinical Trial Program at Cedars-Sinai, about why the recently approved Alzheimer’s medication lecanemab—shown to slow the …

La Administración de Drogas y Alimentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó recientemente la aprobación de lecanemab, el primer tratamiento para la enfermedad de Alzheimer en obtener la aprobación desde el lanzamiento …

The U.S. Food and Drug Administration (FDA) recently granted approval to lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago. Sold under the brand name Leqembi, the new drug …